Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab + SOX for Adjuvant Stage IIIB-IIIC Gastric Cancer
NCT06036745Phase 2Recruiting
- Sponsor
- Shanghai Minimally Invasive Surgery Center
- Start
- Jul 2022
- Primary completion
- Jul 2023
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of pembrolizumab in gastric cancer (GC), sponsored by Shanghai Minimally Invasive Surgery Center. Started Jul 2022; status: recruiting.
02
Drugs
03
Conditions
gastric cancer (GC)
Beyond the preview
Go deeper on NCT06036745.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06036745.